De-escalated Induction Therapy and Thiotepa/Busulfan-based Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2024.11.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Robert Puckrin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tom Baker Cancer Centre and University of Calgary, Calgary, Canada. Electronic address: robert.puckrin@ahs.ca. Hauptthemen laut MEDLINE: Thiotepa, Central Nervous System Neoplasms, Busulfan, Induction Chemotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Thiotepa-based autologous stem cell transplantation (ASCT) improves survival in primary central nervous system lymphoma (PCNSL), but > 30% of patients are unable to undergo ASCT following commonly used intensive induction regimens. METHODS: This retrospective population-based study included consecutive patients ≥ 18 years old with PCNSL who were intended for ASCT in Alberta, Canada between 2011 and 2022. A reduced-intensity induction protocol was further abbreviated in 2018 to decrease toxicity and expediate ASCT by incorporating rituximab, procarbazine, and only 2 doses of high-dose methotrexate and 1 cycle of high-dose cytarabine before consolidation with thiotepa-busulfan conditioning. Progression-free survival (PFS) and overall survival (OS) were determined using the Kaplan-Meier method. RESULTS: Among 71 patients with median age 58 years (range 26-72), ASCT was completed in 56 (79%), with the transplantation rate among patients > 60 years old increasing by 30% following the abbreviation of induction therapy. With median follow-up time 3.9 years, 4-year PFS and OS were 69% (95% CI 56%-79%) and 80% (95% CI 67%-88%) for all patients and 75% (95% CI 57%-86%) and 85% (95% CI 68%-93%) for ASCT recipients, respectively. There was 1 death due to treatment-related mortality during induction and none after ASCT, including among 17 transplanted patients > 60 years old. CONCLUSION: An abbreviated induction regimen followed by thiotepa-busulfan-based ASCT achieves high transplantation rates with low risks of relapse and treatment-related mortality, thereby providing an effective treatment strategy for PCNSL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tom Baker Cancer Centre and University of Calgary, Calgary, Canada. Electronic address: robert.puckrin@ahs.ca.
- Tom Baker Cancer Centre and University of Calgary, Calgary, Canada.
- Cross Cancer Institute and University of Alberta, Edmonton, Canada.
Zitieren
APA
Puckrin, R., Stewart, C., Owen, C., Street, L. E., Perry, S., Duggan, P., Shafey, M., Chua, N., & Stewart, D. A. (2025). De-escalated Induction Therapy and Thiotepa/Busulfan-based Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.11.008
Vancouver
Puckrin R, Stewart C, Owen C, Street LE, Perry S, Duggan P, et al. De-escalated Induction Therapy and Thiotepa/Busulfan-based Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.11.008
BibTeX
@article{Puckrin2025,
author = {Puckrin, Robert and Stewart, Colin and Owen, Carolyn and Street, Lesley E and Perry, Sarah and Duggan, Peter and Shafey, Mona and Chua, Neil and Stewart, Douglas A},
title = {De-escalated Induction Therapy and Thiotepa/Busulfan-based Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2024.11.008}
}
EUVIMED